Two Landmark Approvals for MASH in One Week

Published on: LinkedIn (Spencer Knight)

In just five days, two breakthrough approvals have reshaped treatment for metabolic dysfunction-associated steatohepatitis (MASH). The European Commission approved Madrigal’s Rezdiffra, the first MASH therapy in Europe, while the U.S. FDA granted accelerated approval for Novo Nordisk’s Wegovy in MASH with fibrosis. These decisions mark the first wave of dedicated therapies for a disease that affects millions worldwide.

👉 Read the full article: Two Approvals for MASH in 5 Days

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.